JP2018515556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515556A5 JP2018515556A5 JP2017560309A JP2017560309A JP2018515556A5 JP 2018515556 A5 JP2018515556 A5 JP 2018515556A5 JP 2017560309 A JP2017560309 A JP 2017560309A JP 2017560309 A JP2017560309 A JP 2017560309A JP 2018515556 A5 JP2018515556 A5 JP 2018515556A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- disease
- cancer
- compound
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 206010009887 colitis Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 206010016654 Fibrosis Diseases 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 229940122849 Autotaxin inhibitor Drugs 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 208000003251 Pruritus Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 230000003176 fibrotic effect Effects 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 206010063409 Acarodermatitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010064190 Cholestatic pruritus Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012504 Dermatophytosis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000003164 Diplopia Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 206010016936 Folliculitis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 241001460074 Microsporum distortum Species 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 206010034665 Peritoneal fibrosis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 241000447727 Scabies Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 201000009861 cutaneous mycosis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 230000000642 iatrogenic effect Effects 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 231100000862 numbness Toxicity 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940100688 oral solution Drugs 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000005687 scabies Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002374 sebum Anatomy 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021071253A JP7274521B2 (ja) | 2015-05-27 | 2021-04-20 | オートタキシン阻害剤とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167216P | 2015-05-27 | 2015-05-27 | |
| US62/167,216 | 2015-05-27 | ||
| PCT/US2016/033933 WO2016191427A1 (en) | 2015-05-27 | 2016-05-24 | Autotaxin inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021071253A Division JP7274521B2 (ja) | 2015-05-27 | 2021-04-20 | オートタキシン阻害剤とその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515556A JP2018515556A (ja) | 2018-06-14 |
| JP2018515556A5 true JP2018515556A5 (enExample) | 2019-06-27 |
| JP6873919B2 JP6873919B2 (ja) | 2021-05-19 |
Family
ID=57393709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560309A Active JP6873919B2 (ja) | 2015-05-27 | 2016-05-24 | オートタキシン阻害剤とその使用 |
| JP2021071253A Active JP7274521B2 (ja) | 2015-05-27 | 2021-04-20 | オートタキシン阻害剤とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021071253A Active JP7274521B2 (ja) | 2015-05-27 | 2021-04-20 | オートタキシン阻害剤とその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10632104B2 (enExample) |
| EP (2) | EP3302490B1 (enExample) |
| JP (2) | JP6873919B2 (enExample) |
| KR (2) | KR20240060887A (enExample) |
| CN (2) | CN107921048A (enExample) |
| AU (4) | AU2016268250B2 (enExample) |
| BR (1) | BR122023011445B1 (enExample) |
| CA (1) | CA2986759C (enExample) |
| EA (2) | EA039684B1 (enExample) |
| ES (1) | ES2915267T3 (enExample) |
| IL (2) | IL280863B2 (enExample) |
| MX (2) | MX2017015225A (enExample) |
| SG (1) | SG10201911204WA (enExample) |
| WO (1) | WO2016191427A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015077503A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
| CN107021915A (zh) * | 2017-04-27 | 2017-08-08 | 李亚庆 | 一种治疗妇科炎症的化合物及制备方法和应用 |
| EP3668993A4 (en) * | 2017-08-14 | 2021-05-12 | Camp4 Therapeutics Corporation | HEPATIC DISEASE TREATMENT METHODS |
| WO2019172651A1 (ko) | 2018-03-06 | 2019-09-12 | 주식회사 엘지화학 | 편광판 및 이를 포함하는 화상 표시 장치 |
| CN113056266A (zh) * | 2018-09-18 | 2021-06-29 | 梅塔科林公司 | 用于治疗疾病的法尼醇x受体激动剂 |
| CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| IL313660A (en) | 2021-12-22 | 2024-08-01 | Camp4 Therapeutics Corp | Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs |
| CN114767863B (zh) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | 一种enpp2基因或蛋白在调控结直肠癌细胞中的应用 |
| CA3251769A1 (en) * | 2022-05-03 | 2023-11-09 | Sabre Therapeutics Llc | POLYMORPHIC AND SALINE FORMS OF THE AUTOTAXIN INHIBITOR CUDETAXESTAT |
| US20250281486A1 (en) * | 2022-05-05 | 2025-09-11 | The Trustees Of Indiana University | Therapeutic strategies to manage facial contractures post injury |
| GR1010570B (el) | 2022-12-22 | 2023-11-17 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., | 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης |
| TW202502735A (zh) * | 2023-03-02 | 2025-01-16 | 印度商吉德斯生命科學有限公司 | 新穎atx抑制劑 |
| CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
| US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
| DE69316741T2 (de) | 1992-11-10 | 1998-09-10 | Caterpillar Inc | Magnetventil |
| US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
| US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
| US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
| JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
| MXPA03002911A (es) | 2000-10-03 | 2003-09-10 | Lilly Icos Llc | Compuestos quimicos. |
| DE60234760D1 (de) | 2001-04-11 | 2010-01-28 | Idenix Cayman Ltd | Phenylindole zur behandlung von hiv |
| DE60203529T2 (de) | 2001-09-27 | 2006-03-16 | F. Hoffmann-La Roche Ag | Indolderivate als cox-ii-inhibitoren |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| CA2495915A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| DK1537078T3 (da) | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| ATE537825T1 (de) | 2003-05-19 | 2012-01-15 | Irm Llc | Immunosuppressive verbindungen und zusammensetzungen |
| DK1701940T3 (da) | 2003-12-23 | 2008-09-08 | Lundbeck & Co As H | 2-(1H-indolylsulfanyl)-bensylaminderivater som SSRI |
| US7905958B2 (en) | 2004-05-19 | 2011-03-15 | Sumitomo Electric Industries, Ltd. | Group III-nitride semiconductor crystal and manufacturing method thereof, and group III-nitride semiconductor device |
| KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
| WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| WO2006050236A2 (en) | 2004-11-01 | 2006-05-11 | Nuada, Llc | Compounds and methods of use thereof |
| US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
| AR054394A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| US7921385B2 (en) | 2005-10-03 | 2011-04-05 | Luminescent Technologies Inc. | Mask-pattern determination using topology types |
| US7705028B2 (en) * | 2005-12-19 | 2010-04-27 | Glaxosmithkline Llc | Farnesoid X receptor agonists |
| CA2690762C (en) | 2007-06-15 | 2016-06-14 | Glenn Prestwich | .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof |
| DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
| DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
| US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| US20110110886A1 (en) | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| WO2010040080A1 (en) | 2008-10-03 | 2010-04-08 | Abby Louise Parrill-Baker | Mechanism-based inactivators of autotaxin |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| SG171809A1 (en) | 2008-12-01 | 2011-07-28 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| ES2547124T3 (es) | 2009-04-02 | 2015-10-01 | Merck Patent Gmbh | Inhibidores de autotaxina |
| JP5767205B2 (ja) | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| MX2011010203A (es) | 2009-04-02 | 2011-10-14 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de autotaxina. |
| US8445200B2 (en) | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
| US10519504B2 (en) | 2009-05-11 | 2019-12-31 | Berg Llc | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| JP2010267037A (ja) | 2009-05-14 | 2010-11-25 | Fujitsu Ltd | ディスクアレイ装置 |
| AU2010250838B2 (en) | 2009-05-20 | 2016-01-21 | Eth Zurich | Targeting microRNAs for metabolic disorders |
| US8343934B2 (en) | 2009-06-30 | 2013-01-01 | University Of Memphis | Diverse lead compound autotaxin inhibitors |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
| WO2011049433A1 (en) * | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
| WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| EP2552914B1 (de) | 2010-03-26 | 2015-11-11 | Merck Patent GmbH | Benzonaphthyridinamine als autotaxin-inhibitoren |
| EP2558115B1 (en) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Methods for treating metabolic disorders using fgf |
| JP2013536200A (ja) * | 2010-08-20 | 2013-09-19 | アミラ ファーマシューティカルス，インコーポレーテッド | オートタキシン阻害剤およびその使用 |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| WO2012100018A1 (en) | 2011-01-20 | 2012-07-26 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
| CN103476416B (zh) | 2011-02-18 | 2016-09-21 | 梅迪维新技术公司 | 治疗高血压的化合物和方法 |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| US20140086839A1 (en) * | 2011-03-17 | 2014-03-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| GB2494154B (en) | 2011-08-31 | 2017-11-29 | Metaswitch Networks Ltd | Conditional telecommunications |
| KR20130029948A (ko) | 2011-09-16 | 2013-03-26 | 현대중공업 주식회사 | 용접 캐리지 이동용 가이드레일 |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
| EP2771325B1 (en) | 2011-10-28 | 2017-06-28 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
| JP2013129632A (ja) | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Ｅｎｐｐ２阻害化合物 |
| US20130270634A1 (en) | 2012-04-12 | 2013-10-17 | Richtek Technology Corporation | High voltage device and manufacturing method thereof |
| PT2861566T (pt) | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| AU2013322838B2 (en) | 2012-09-25 | 2018-02-01 | F. Hoffmann-La Roche Ag | New bicyclic derivatives |
| CN104968656B (zh) | 2012-12-19 | 2017-08-11 | 诺华股份有限公司 | 自分泌运动因子抑制剂 |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
| US9951026B2 (en) | 2013-09-17 | 2018-04-24 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| WO2015042053A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| US10150737B2 (en) | 2013-11-05 | 2018-12-11 | Bayer Cropscience Aktiengesellschaft | Compounds for controlling arthropods |
| US9926318B2 (en) | 2013-11-22 | 2018-03-27 | Pharmakea, Inc. | Tetracyclic autotaxin inhibitors |
| WO2015077503A1 (en) | 2013-11-22 | 2015-05-28 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| CA2929062A1 (en) | 2013-11-22 | 2015-05-28 | Basf Se | N-acylimino heterocyclic compounds |
| CL2016001118A1 (es) | 2013-11-22 | 2016-12-02 | Basf Se | Compuestos heterocíclicos de n-acilimino |
| US9051320B1 (en) | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
-
2016
- 2016-05-24 AU AU2016268250A patent/AU2016268250B2/en active Active
- 2016-05-24 KR KR1020247014437A patent/KR20240060887A/ko not_active Ceased
- 2016-05-24 SG SG10201911204WA patent/SG10201911204WA/en unknown
- 2016-05-24 EP EP16800640.1A patent/EP3302490B1/en active Active
- 2016-05-24 IL IL280863A patent/IL280863B2/en unknown
- 2016-05-24 MX MX2017015225A patent/MX2017015225A/es unknown
- 2016-05-24 CN CN201680044106.9A patent/CN107921048A/zh active Pending
- 2016-05-24 EP EP22159828.7A patent/EP4026549A1/en active Pending
- 2016-05-24 JP JP2017560309A patent/JP6873919B2/ja active Active
- 2016-05-24 ES ES16800640T patent/ES2915267T3/es active Active
- 2016-05-24 CN CN202211516732.7A patent/CN116059203A/zh active Pending
- 2016-05-24 EA EA202091731A patent/EA039684B1/ru unknown
- 2016-05-24 CA CA2986759A patent/CA2986759C/en active Active
- 2016-05-24 EA EA201792604A patent/EA036337B1/ru unknown
- 2016-05-24 WO PCT/US2016/033933 patent/WO2016191427A1/en not_active Ceased
- 2016-05-24 US US15/574,769 patent/US10632104B2/en active Active
- 2016-05-24 KR KR1020177036376A patent/KR102663569B1/ko active Active
- 2016-05-24 BR BR122023011445-0A patent/BR122023011445B1/pt active IP Right Grant
-
2017
- 2017-11-20 IL IL255764A patent/IL255764B/en active IP Right Grant
- 2017-11-27 MX MX2022007436A patent/MX2022007436A/es unknown
-
2020
- 2020-03-17 US US16/821,365 patent/US12458627B2/en active Active
- 2020-09-22 AU AU2020239656A patent/AU2020239656B2/en active Active
-
2021
- 2021-04-20 JP JP2021071253A patent/JP7274521B2/ja active Active
-
2022
- 2022-09-06 AU AU2022228098A patent/AU2022228098A1/en not_active Abandoned
-
2024
- 2024-11-12 AU AU2024264577A patent/AU2024264577A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515556A5 (enExample) | ||
| JP2021502403A5 (enExample) | ||
| FI4034104T3 (fi) | Menetelmiä ja yhdisteitä mutantin p53-toiminnan palauttamiseksi | |
| JP2020535134A5 (enExample) | ||
| JP2020510664A5 (enExample) | ||
| JP2019131579A5 (enExample) | ||
| JP2021119158A5 (enExample) | ||
| JP2017529389A5 (enExample) | ||
| JP2016199576A5 (enExample) | ||
| JP2019517491A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| JP2021512114A5 (enExample) | ||
| JP2018516963A5 (enExample) | ||
| JP2015523546A5 (enExample) | ||
| JP2015535270A5 (enExample) | ||
| UA101348C2 (ru) | 1,2,4-оксадиазольные соединения для лечения аутоиммунных заболеваний | |
| JP2019507777A5 (enExample) | ||
| WO2007122812A1 (ja) | 炎症性腸疾患治療薬 | |
| KR20190128619A (ko) | 의약에서 사용하기 위한 술폭시알킬 오르가노니트로 및 관련 화합물 및 제약 조성물 | |
| JP2018514535A5 (enExample) | ||
| JP2019527239A5 (enExample) | ||
| JP2019535812A5 (enExample) | ||
| JP2007504168A5 (enExample) | ||
| JP2009543804A5 (enExample) | ||
| RU2019110779A (ru) | Новые схемы введения агонистов fxr |